The gut microbiome: what every gastroenterologist needs to know

被引:13
作者
Mullish, Benjamin H. [1 ,2 ]
Quraishi, Mohammed Nabil [3 ,4 ]
Segal, Jonathan P. [2 ]
Ianiro, Gianluca [5 ]
Iqbal, Tariq H. [3 ,4 ]
机构
[1] Imperial Coll Sci Technol & Med, Dept Metab Digest & Reprod, Div Digest Dis, London, England
[2] Imperial Coll Healthcare NHS Trust, St Marys Hosp, Dept Gastroenterol & Hepatol, London, England
[3] Univ Birmingham, Microbiome Treatment Ctr, Birmingham, W Midlands, England
[4] Univ Hosp Birmingham NHS Fdn Trust, Dept Gastroenterol, Birmingham, W Midlands, England
[5] Univ Cattolica Sacro Cuore, Ctr Digest Dis, Fdn Policlin Univ Agostino Gemelli IRCCS, Rome, Italy
关键词
gut microbiome; faecal microbiota transplant; probiotics; Clostridioides difficile infection; inflammatory bowel disease; FECAL MICROBIOTA; FAECALIBACTERIUM-PRAUSNITZII; PROBIOTIC THERAPY; T-CELLS; TRANSPLANTATION; RECURRENT; EFFICACY; COLITIS; HEALTH; METAANALYSIS;
D O I
10.1136/flgastro-2019-101376
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The mucosal surfaces of the body are characterised by complex, specialised microbial communities, often referred to as the microbiome. However, only much more recently-with the development of technologies allowing exploration of the composition and functionality of these communities-has meaningful research in this area become feasible. Over the past few years, there has been rapid growth in interest in the gut microbiome in particular, and its potential contribution to gastrointestinal and liver disease. This interest has already extended beyond clinicians to pharmaceutical companies, medical regulators and other stakeholders, and is high profile among patients and the lay public in general. Such expansion of knowledge holds the intriguing potential for translation into novel diagnostics and therapeutics; however, being such a nascent field, there remain many uncertainties, unanswered questions and areas of debate.
引用
收藏
页码:118 / 127
页数:10
相关论文
共 93 条
  • [51] McDonald LC, 2018, CLIN INFECT DIS, V66, pE1, DOI [10.1093/cid/ciy149, 10.1093/cid/cix1085]
  • [52] The composition of the gut microbiota throughout life, with an emphasis on early life
    Miguel Rodriguez, Juan
    Murphy, Kiera
    Stanton, Catherine
    Ross, R. Paul
    Kober, Olivia I.
    Juge, Nathalie
    Avershina, Ekaterina
    Rudi, Knut
    Narbad, Arjan
    Jenmalm, Maria C.
    Marchesi, Julian R.
    Carmen Collado, Maria
    [J]. MICROBIAL ECOLOGY IN HEALTH AND DISEASE, 2015, 26
  • [53] Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis
    Mima, Kosuke
    Nishihara, Reiko
    Qian, Zhi Rong
    Cao, Yin
    Sukawa, Yasutaka
    Nowak, Jonathan A.
    Yang, Juhong
    Dou, Ruoxu
    Masugi, Yohei
    Song, Mingyang
    Kostic, Aleksandar D.
    Giannakis, Marios
    Bullman, Susan
    Milner, Danny A.
    Baba, Hideo
    Giovannucci, Edward L.
    Garraway, Levi A.
    Freeman, Gordon J.
    Dranoff, Glenn
    Garrett, Wendy S.
    Huttenhower, Curtis
    Meyerson, Matthew
    Meyerhardt, Jeffrey A.
    Chan, Andrew T.
    Fuchs, Charles S.
    Ogino, Shuji
    [J]. GUT, 2016, 65 (12) : 1973 - 1980
  • [54] Fusobacterium nucleatum and T Cells in Colorectal Carcinoma
    Mima, Kosuke
    Sukawa, Yasutaka
    Nishihara, Reiko
    Qian, Zhi Rong
    Yamauchi, Mai
    Inamura, Kentaro
    Kim, Sun A.
    Masuda, Atsuhiro
    Nowak, Jonathan A.
    Nosho, Katsuhiko
    Kostic, Aleksandar D.
    Giannakis, Marios
    Watanabe, Hideo
    Bullman, Susan
    Milner, Danny A.
    Harris, Curtis C.
    Giovannucci, Edward
    Garraway, Levi A.
    Freeman, Gordon J.
    Dranoff, Glenn
    Chan, Andrew T.
    Garrett, Wendy S.
    Huttenhower, Curtis
    Fuchs, Charles S.
    Ogino, Shuji
    [J]. JAMA ONCOLOGY, 2015, 1 (05) : 653 - 661
  • [55] Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis
    Mimura, T
    Rizzello, F
    Helwig, U
    Poggioli, G
    Schreiber, S
    Talbot, IC
    Nicholls, RJ
    Gionchetti, P
    Campieri, M
    Kamm, MA
    [J]. GUT, 2004, 53 (01) : 108 - 114
  • [56] Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
    Morgan, Xochitl C.
    Tickle, Timothy L.
    Sokol, Harry
    Gevers, Dirk
    Devaney, Kathryn L.
    Ward, Doyle V.
    Reyes, Joshua A.
    Shah, Samir A.
    LeLeiko, Neal
    Snapper, Scott B.
    Bousvaros, Athos
    Korzenik, Joshua
    Sands, Bruce E.
    Xavier, Ramnik J.
    Huttenhower, Curtis
    [J]. GENOME BIOLOGY, 2012, 13 (09): : R79
  • [57] The implementation of omics technologies in cancer microbiome research
    Mullish, Benjamin H.
    Osborne, Laura S.
    Marchesi, Julian R.
    McDonald, Julie A. K.
    [J]. ECANCERMEDICALSCIENCE, 2018, 12
  • [58] Mullish BH, 2018, GUT, V67, P1920, DOI [10.1136/gutjnl-2018-316818, 10.1016/j.jhin.2018.07.037]
  • [59] Fusobacterium varium localized in the colonic mucosa of patients with ulcerative colitis stimulates species-specific antibody
    Ohkusa, T
    Sato, N
    Ogihara, T
    Morita, K
    Ogawa, M
    Okayasu, I
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2002, 17 (08) : 849 - 853
  • [60] Olesen SW, 2016, NAT MICROBIOL, V1, DOI [10.1038/NMICROBIOL.2016.228, 10.1038/nmicrobiol.2016.228]